Biointerface Research in Applied Chemistry
Open-Access Journal (ISSN: 2069-5837)

Review
Volume 13, Issue 6, 2023, 526
https://doi.org/10.33263/BRIAC136.526

Biomarkers in Diabetes Mellitus (DM) - with a Special Focus on miRNAs as Future Markers for Diagnosis of DM

Mudasir J. Makhdoomi [1], Gresh Chander [2,*], Wasia Showkat [1], Vandana Golhani [3], Abid Ali Sheikh [4,*]

[1] Department of Endocrinology, Sher-I-Kashmir Institute of Medical Sciences (SKIMS) Srinagar- 190011, (J&K), India; mudasirbio786@gmail.com (M.J.M.); wani.wasia@gmail.com (W.S.);
[2] ICMR-CAR School of Biotechnology, Shri Mata Vaishno Devi University, Katra-182320 (J&K); greshzoology143@gmail.com (G.C.);
[3] All India Institute of Medical Sciences Bhopal, Madhya Pradesh 462026; vandanagolhani1991@gmail.com (V.G.);
[4] National Institute of Biologicals (NIB) Sector-62 Noida-201 309 (Uttar Pradesh), India.;abidalis2007@gmail.com (A.A.S.);
* Correspondence: greshzoology143@gmail.com (G.C.), abidalis2007@gmail.com (A.A.S.);

Scopus Author ID 55250138800
Received: 14.09.2022; Accepted: 24.11.2022; Published: 4.02.2023

Abstract: Diabetes mellitus, which affects 463 million people globally and is a progressive disease that can deteriorate if left untreated, is quickly assuming the status of a possible pandemic. To decrease the risk of prediabetes progressing to diabetes, improved techniques for identifying it are necessary. Current biomarkers, such as glucose and glycated hemoglobin (HbA1c), have intermediate sensitivity and specificity and can be incorrect in some clinical situations. As a result, combining various indicators may help to more precisely identify those who are at high risk of acquiring diabetes. Late investigations have recommended that the statement of biomolecules, particularly microRNAs (miRNAs), changes during the movement of DM and their unique changes with DM and its connected confusions. miRNAs are autocrine and endocrine controllers of gene expression, and because of their dependability in body liquids, they can be utilized as non-invasive forecast instruments in DM. In this audit, we center around biomolecules, particularly miRNAs, that could be likely biomarkers in DM.

Keywords: diabetes mellitus; biomarkers; microRNAs; gestational diabetes.

1. Introduction

More than 463 million individuals are experiencing diabetes mellitus (DM), just about multiple times more than the appraisals ten years prior [1]. As indicated by the evaluations of the Global Diabetes League (IDF), 552 million individuals are required to be diabetic by 2030 around the world [2]. Subsequently, the human populace overall gives off an impression of being amidst a pestilence of diabetes [3]. In industrialized nations, DM is the main source of visual deficiency, renal disappointment, and non-horrendous lower-appendage removals. Plus, patients experiencing diabetes additionally have a greater danger of creating cardiovascular problems and stroke, delivering DM a weighty financial weight [4]. The commonness of diabetes is expanding emotionally in youngsters and grown-ups because of current ways of life related to decreased actual work and heftiness [5]. Reports from World Wellbeing Association (WHO) demonstrate

that DM is one of the main sources of bleakness and mortality around the world, with individuals in Southeast Asia and the Western Pacific being most at threat [6] [7]. As per IDF, there were 78.3 million diabetic individuals in South East Asia in 2015 and 88 million in 2021, which is additionally expected to increment to 140.2 million by 2040 (56% increment) [8]. DM is quickly acquiring the situation with a possible pestilence in India with 77 million cases. The quantity of individuals with diabetes in India has expanded from 26 million in 1990 to 65 million in 2016 [9]. INDAB ICMR people group-based examination in 14 Indian states showed the predominance of diabetes, with the most elevated in Chandigarh (13.6%), trailed by Tamil Nadu (10.4%), Punjab (10%), Andhra Pradesh (8.4%), Karnataka (7.5%), Gujarat (7.1%), Mizoram (5.8%), Assam (5.5%), Jharkhand (5.3%), Manipur (5.1%), Andhra Pradesh (5.1%), Meghalaya (4.5%), Bihar (4.3%). Chandigarh has the most elevated Gross domestic product (Net homegrown per capita) recommended the job of the way of life and diet in the inclination of diabetes [10]. According to the ICMR (Indian Chamber of Clinical Exploration) and WHO (World Wellbeing Association) examination, the pervasiveness of diabetes is more in non-industrial nations like India contrasted to created nations. According to the study of disease transmission, the predominance of diabetes in India is projected to be around 134.3 million constantly in 2045 [12].

Albeit the beginning and etiologies of Diabetes mellitus can be diverse, the infection is perpetually portrayed by dysregulation of blood glucose homeostasis coming about because of the inadequacy of pancreatic β-cells to discharge fitting measures of insulin to support the requests or deformity in the insulin receptor [13]. Diabetes can be essential or auxiliary. Type 1 and Type 2 diabetes mellitus (T1DM and T2DM) are the two chief types of infection. T1D, otherwise called immune system diabetes, fundamentally seen during youth or puberty, is an ongoing metabolic issue where insulin lack is portrayed by pancreatic β-cell misfortune[14] and represents 5-8% of all diabetes cases. The shortfall of β-cells in T1D brings about hyperglycemia, which is, by and large, overseen exogenously by overseeing insulin infusions [15,16]. Thusly, T1D is joined by miniature and full-scale vascular intricacies, which can be ongoing or intense [17-20]. According to American Diabetes Affiliation (ADA) 2016, the symptomatic rules for deciding diabetes mellitus depend on the signs and indications related to unusual glucose digestion, paying little mind to the diabetes type and period of beginning [21]. Maximum cases of T1D T1D stay undiscovered, which can cause genuine ramifications. Thusly, symptomatic markers, frequently called 'biomarkers' utilizing a foundation of hereditary markers, metabolic markers, and islet autoantibodies (AAb), are acquiring notoriety in the T1D determination at the beginning phases.

T2DM can be essential when there is an imperfection in insulin receptors or because of optional clauses that can prompt diabetes [22]. The pathogenesis of this illness is firmly connected to hereditary and ecological/way of life factors, for example, hypercaloric nutrition, absence of activity, stationary way of life, modernization, and stoutness. T2DM is started by the deficiency of insulin affectability of target tissues, including the liver, skeletal muscles, and fat tissues, which can regularly be repaid by the development of the utilitarian β-cell mass and by an expansion in their insulin secretory movement [23]. Nonetheless, in hereditarily inclined people, β-cells can't support the expanded insulin interest, prompting persistent hyperglycemia prompting the beginning of T2DM. Despite concentrated exploration, the specific reasons for DM stay indistinct. The restorative munitions stockpile accessible today helps fairly control diabetes and related complexities by presenting either OHAs or insulin [24].

The adequacy of these medicines can be radically improved by executing them during the underlying periods of the sickness and by distinguishing new biomarkers anticipating or potentially checking the movement of T1DM and T2DM, which are drawn-out complexities [25]. This survey plans to summarize the information holes in the current examinations and biomarkers presently used to distinguish T1DM/T2DM and discuss the expected utilization of coursing miRNAs as a novel biomarker.

2. Materials and Methods

2.1. Classical biomarkers in diabetes.

As indicated by WHO, analysis of DM depends on blood glucose level estimations in fasting and oral glucose resilience states following 8-10 hours of fasting at 0hr, 1hr, and 2hr spans. An individual is viewed as diabetic if blood glucose levels above 7.0mmol/L (126 mg/dl) in the fasting state and postprandial of > 200 mg/dl are recorded. An individual is viewed as Pre- Diabetic if fasting blood sugars are between (110-126mg/dl) and postprandial (140-200mg/dl). Other serum boundaries, for example, glycated hemoglobin (HbA1c) or lingering C-peptide, can likewise be useful for analyzing DM [26].

2.2. Biomarkers for type 1 diabetes mellitus (T1DM).

The movement of T1DM is moderate (from months to years), conceivably giving longer periods to distinguish and treat people in danger, and is analyzed when more than 80 to 90% of the pancreatic β-cells have been obliterated by the insusceptible framework [27] advances to save the elements of remaining β-cells at the beginning of T1DM have been accounted for utilizing immunosuppressive prescriptions. Until now, 'Serum Biomarkers' are viewed as the most encouraging biomarkers used in identifying prediabetes; be that as it may, their remedial ramifications for expectation and the executives of T1DM must be surely known [28]. Albeit the etiology of T1DM has effectively been set up, there are still a couple of biomarkers like glucose, HbA1c, C-peptide, miRNA, and some specific AAb accessible, which are used for early identification of diabetes [29]. Different pathways associated with the movement/pathogenesis of T1DM and the non-accessibility of suitable biomarkers make it hard to reflect β-cell working and homeostasis of blood glucose levels in the body [30]. This review points out how using biomarkers in early discovery and the executives of T1DM can be helpful.

Moreover, it also features a portion of the clever biomarkers under pipeline research for the helpful administration of T1DM in alleviating diabetes-related complications [31]. Albeit the viability of these medicines is restricted, critical enhancements could presumably be accomplished in case therapeutics are ensnared before phases of the infection when a bigger number of β-cells are as yet present [32]. Autoantibodies, in contradiction of islet antigens, are frequently utilized as biomarkers for T1DM since their quality in the blood is a sign of the sickness. A few autoantibodies have been accounted for. However, those coordinated against islet cells (ICA), tyrosine phosphatase (IA-2 and IA-2β), insulin (IAA), zinc carrier 8 (ZnT8), and glutamate decarboxylase (GADA), are the most dependable for perceiving people in danger of creating T1DM.

Nonetheless, the utilization of islet autoantibodies as biomarkers has certain impediments. For example, they show up somewhat late throughout T1DM and are not reasonable for checking helpful results. Thusly, there is a requirement for extra biomarkers for T1DM to supplement the data acquired from the presence of autoantibodies and other danger factors (age, family ancestry, helplessness qualities, and ecological triggers) [33].

2.3. Type 2 diabetes mellitus (T2DM) biomarkers.

Recent huge populace-based and meta-investigations have distinguished numerous likely hereditary and non-hereditary biomarkers for the danger of T2DM. The mix of hereditary variations and physiologically described pathways works on the order of people with T2DM into subgroups, subsequently preparing an accurate medication approach for T2DM [34]. A sum of 86 meta-analysis and Mendelian randomization reads for the distinguishing proof of hazard components of T2DM, including biomarkers, way of life, natural, dietary, psychosocial elements, and clinical history, announced that 116 of 142 affiliations were genuinely huge at the degree of $p < 0.05$ and 46 at the degrees of $p < 106$ [35].

Persons at risk of fostering T2DM are presently being analyzed by a mix of effectively available serum boundaries (counting glucose, fatty substances, cholesterol, lipoproteins, and HbA1c), actual qualities (weight record, abdomen to-hip proportion, circulatory strain, and sex), and way of life propensities (food utilization, actual latency, and smoking) [36]. By combining these conventional/traditional biomarkers and hazard factors, the likelihood of foreseeing the advancement of the infection goes from 0.85 to 0.90 in a time of 5 to 10 years before the beginning of T2DM. Different particles have arisen as conceivably helpful biomarkers, including chemicals, cytokines, adipokines, ferritin, and C-responsive protein [37].

None of these purported novel biomarkers can independently anticipate T2DM sign productively, yet in the mix; they can accomplish prescient qualities like those with old-style biomarkers. This load of serum boundaries effectively foresees the improvement of T2DM a couple of years ahead of time in people previously showing metabolic modifications. However, they are not explicit for diabetes and can't evaluate infection defenselessness in everybody [38]. The genotypic investigation might supplement the biomarkers for the distinguishing proof of people powerless to foster T2DM further down the road. Be that as it may, up until now, the prescient upsides of genotypic qualities have not surpassed 0.6011. In this way, there is presently a requirement for ahead-of-schedule and way of life-free prescient components empowering doctors to perceive people in danger of creating T2DM [39].

3.MicroRNAs

MicroRNAs (miRNAs) are little noncoding RNA particles of 21 to 23 nucleotides length that capacity as translational repressors by somewhat blending to the 3'untranslated (UTR) locale of target courier RNAs. These controllers of gene expression were first found in *Caenorhabditis elegans* and later on in spineless creatures and plants [40]. As indicated by late gauges, the human genome encodes more than 1600 miRNA antecedents, producing up to 2237 developed miRNAs (www.miRbase.org), every one of which can control many targets. miRNAs are currently all around perceived as significant controllers of quality articulation and as key regulators of a few

organic and neurotic processes [41]. miRNAs are created from stem-circle forerunner RNAs produced from autonomous transcriptional units or introns of protein-coding qualities. These essential records (pri-miRNAs) are first handled to deliver more limited RNA molecules(pre-miRNAs) and afterward sent out to the cytosol, where they are cut to produce the developed types of miRNAs. The developed miRNAs can either be remembered for the RNA-instigated quieting complex (RISC) to direct translational restraint of target mRNAs or be delivered by the cells [42]. In the latter case, the miRNAs are related to proteins and lipoproteins or are stacked inside vesicles delivered in the extracellular space upon plasma layer gabbing or after a combination of multi-vesicular bodies with the plasma membrane [43-45].

3.1. Role of miRNAs in diabetes pathogenesis.

Pancreatic β-cells and insulin target tissues express an obvious arrangement of miRNAs [46]. The vast majority of them are not cell-explicit but are generally conveyed through human tissues. An outstanding special case is addressed by miR-375, a miRNA profoundly enhanced in pancreatic islets that manage the outflow of qualities engaged with chemical emission and β-cell mass extension in light of insulin obstruction [47]. The miRNA articulation profile of β-cells and insulin target tissues is modified both in T1DM and T2DM, probably adding to the weakened capacity of these tissues under ailing states [48] [49]. The islets of prediabetic Gesture mice, a model of T1DM, contain expanded levels of a few miRNAs, including miR-21, - 34a, - 29, and - 146a, which maliciously affect β-cell capacities [50]. The vast majority of these miRNAs and numerous others are adjusted likewise in the islets ob/ob and db, two models of corpulence and T2DM [51]. Curiously, in these creatures, the outflow of miR-29 and - 34a is additionally expanded in insulin target tissues, conceivably adding to insulin obstruction [52]. MiR-143, miR-802, and two closely related miRNAs, miR-103 and -107, were also found to be dysregulated in insulin target tissues of ob/ob mice, dietary animal models of obesity, and diabetic GK rats 25-28 48..

Numerous studies suggested that several miRNAs play an important role in the pathogenesis of diabetes [53]. The failure of different body organs like the liver, skeletal muscle, and fat tissue to be receptive to insulin is, for the most part, alluded to as insulin opposition, bringing about diminished glucose take-up and hyperglycemic conditions in these inert tissues [54]. Solid exploratory proof demonstrates miRNAs' commitment to improving insulin obstruction in corpulence models [55]. miRNA variations associated with diabetes have also been reported in human tissues [56]. More than sixty differentially communicated miRNAs were distinguished in human skeletal muscle biopsies from T2DM patients, with an upregulated articulation of miR-143 and downregulated articulation of two muscle-explicit miRNAs, miR-206 and miR-133a. Curiously, the degree of about 15% of these miRNAs was at that point adjusted in people with disabled glucose resilience, proposing a contribution in the beginning stages of the illness cycle. The articulation of a piece of these miRNAs is constrained by insulin. However, this administrative component seems, by all accounts, to be weakened in diabetic patients. Notwithstanding the progressions in insulin target tissues portrayed above, diabetes brings about huge adjustments in miRNA articulation in veins, heart, retina, and kidneys demonstrating the association of these noncoding RNAs in long-haul diabetes complications [57].

3.2. A functional role for circulating miRNAs.

The revelation of miRNAs has added another layer of intricacy to the instruments controlling the exercises of β-cells. Because of concentrated endeavors, our insight into these noncoding RNAs' commitment to separating and controlling specific elements of insulin-emitting cells is persistently improving [58]. Additionally, the quality administrative exercises achieved inside the cells delivering them, a few miRNAs are found in blood and other body liquids in relationship with proteins, microvesicles, or potentially lipoprotein edifices [59]. The scientific studies carried out throughout the last decade were based on the hypothesis that changes in miRNA levels are paralleled by consistent modifications in miRNA activity and vice versa. We currently realize that this isn't the situation. Indeed, just a little part of the miRNAs are bound to AGO2 [60-63]. The purpose of circling miRNAs still needs to be set up. However, *in-vitro* shows that miRNAs transported by exosomes or high-thickness lipoprotein (HDL) can be moved from the idle structure to beneficiary cells. This raises the captivating chance of the association of miRNAs in a clever cell-to-cell communique mode [64].

Circulating miRNAs are truly steady and impervious to RNAse treatment, freezing/defrosting cycles, and other intense test conditions [65]. Therefore, serum or plasma tests can be put away at - 20°C or - 80°C for as long as a while without huge miRNA corruption, recommending that these little RNA atoms are adequately powerful to fill in as biomarkers [66]. In addition, coursing miRNAs present a few different benefits as expected biomarkers as they are discovered in blood as well as in other effectively available organic liquids (like pee, salivation, amniotic liquid, and maternal milk) and can be recognized by exceptionally touchy and explicit quantitative PCR strategies and a large portion of them are transformative saved, working with the interpretation of results acquired from in-vivo creature studies to human medical services. Also, miRNA serum profiles of sound givers are moderately homogenous and can be estimated in both serum and plasma [67, 68].

3.3. miRNAs as diabetes biomarkers.

Utilizing blood miRNAs as biomarkers is moderately new and were first proposed for recognizing various types of malignancy, immune system illnesses, and sepsis [69]. Late examinations have investigated the miRNA profile in serum, plasma, or platelets trying to foster new ways to deal with anticipated diabetes improvement and movement [70]. An expansion in the outflow of seven diabetes-related miRNAs (miR-9, - 29a, - 30d, - 34a, - 124a, - 146a and - 375) was recognized in T2DM patients contrasted with pre-diabetic or T2DM powerless subjects.

Nonetheless, no distinctions were seen between typical glucose lenient and prediabetic people demonstrating that the level of these miRNAs isn't appropriate to anticipate T2DM susceptibility [71]. Additionally, miRNAs present in the blood and exosomes of 265 patients with various ailments were estimated and discovered to be related to a metabolic condition. An up-guideline of miR-27a, - 150,- 192, - 320a, and - 375 in T2DM people were distinguished, and a solid relationship was seen between raised fasting glucose focuses and change of miR-27a and miR-320a levels [72]. These revolutionary studies revealed the potential of miRNAs as biomarkers for T2DM. Nevertheless, the outcomes' heterogeneity highlights the necessity for future studies to distinguish solid miRNA marks for T2DM. A comparative methodology was endeavored to

distinguish new biomarkers foreseeing the obliteration of recovery of lingering β-cells in T1DM. Examination of two companions recently analyzed for T1DM to an age-coordinated with control bunch uncovered a gathering of miRNAs (miR-24, - 25, - 26a, - 27a, - 27b, - 29a, - 30a-5p, - 148a, - 152, - 181a, - 200a and - 210) that were differentially communicated in diabetes accomplices and not in control gatherings. In addition, miR-25 levels were found to correspond with leftover β-cell work (C-peptide estimation) and satisfactory glycemic control (HbA1c levels) 90 days after the infection began [73]. Assessment of the blood miRNA profiles of 20 freshly determined T1DM patients to that of healthy persons revealed that out of 206 miRNAs distinguished in the serum of both groups, 64 were inversely articulated in T1DM. Strangely, a portion of these miRNAs controls the elements of resistant cells (miR-31, - 146a - 155, - 181a, - 199a) or β-cells (miR-9, 34a) [74].

miR-375, profusely articulated in the islets of Langerhans, has been proposed as an appropriate biomarker to distinguish β-cell passing and foresee the improvement of T1DM in creature models. Albeit gigantic β-cell misfortune by the organization of streptozocin caused a sensational ascent in flowing levels of this miRNA, its plasma levels were altogether expanded in Gesture mice fourteen days before the beginning of T1DM, and changes in miR-375 levels after β-cell passing were short-lived [75]. Accordingly, these promising discoveries in mice should be confirmed in people where the decrease of the β-cell mass spans longer periods. Rather than examining plasma tests, different investigations zeroed in on platelets and estimated the statement of explicit miRNAs thought to assume significant parts in the invulnerable response. Reduced articulation of miR-21a and miR-93 has been seen in fringe blood mononuclear cells (PBMC) of T1DM patients contrasted with sound controls. The decrease of miR-21a could be repeated by hatching PBMC from control people within sight of glucose, recommending that it very well might be the outcome of persistent hyperglycemia [76]. miRNA articulation has been investigated in blood lymphocytes from T1DM people, and an ascent in miR-326 levels was seen that related to the islet immune system assault [77]. The essential objective of the last two examinations was to recognize miRNAs possibly engaged with improving the illness. Notwithstanding, since a huge part of serum miRNAs are delivered by platelets, it is conceivable that the miRNA changes in PBMC or potentially lymphocytes seen in these two investigations might yield distinguishable contrasts in plasma levels allowing observing the immune system reaction [78].

4. Prediction of Diabetes Complications

T1DM and T2DM are related to long-haul miniature and macrovascular inconveniences that overwhelmingly affect life quality and hope [59]. The disclosure of biomarkers equipped for recognizing people in danger of encountering genuine inconveniences like retinopathy, nephropathy, or cardiovascular problems would allow tailoring the helpful methodologies and limiting the normal effects of the infection [79]. However, the dependable biomarkers for these drawn-out complexities are as yet absent. Cardiovascular difficulties comprise the primary worry since they represent up to 80% of untimely mortality in diabetic patients [79]. Avoidance or even a deferral of these entanglements would address a significant progression in the treatment of diabetes. A one-of-a-kind plasma miR-126 was recognized in T2DM patients showing the most grounded relationship with T2DM and connection with the event of subclinical and plain course

infections [80]. Strangely, the down-guideline of miR-126 in blood tests obtained from patients experiencing coronary supply route infection has additionally been accounted for [81].

This miRNA is profoundly improved in endothelial cells, where it assumes significant parts in cell homeostasis and vascular trustworthiness. Also, the degree of miR-126 delivered in apoptotic bodies is decreased by the constant openness of endothelial cells to raised blood glucose levels making this miRNA an optimal applicant biomarker for checking diabetic vascular inconveniences. Another endothelial cell miRNA that merits further consideration is miR-503. The level of this little noncoding RNA is up-directed in muscle biopsies and infringes blood in the determined plasma of diabetic patients with appendage ischemia [82]. Curiously, nearby hindrances of the miR-503 model of appendage ischemia had the option to work on vascular mending and bloodstream recuperation [83]. Other flowing miRNAs have additionally been recommended as demonstrative markers for different cardiovascular illnesses. Yet, their utilization in anticipating or checking cardiovascular entanglements in diabetic patients still needs to be researched. Kidney sickness influences 20-30% of T1DM and T2DM patients. Microalbuminuria was recently proposed as a biomarker to anticipate the event of this significant difficulty. Yet, ongoing investigations uncovered that a huge part of diabetic patients goes through renal disappointment previously or even without discernible microalbuminuria [84]. Flowing miRNAs address a decent elective method of checking renal disappointment in diabetic patients. They are not killed by hemodialysis and have effectively been tried in various renal infections with promising outcomes in both creature models and human patients. Surely, a relationship was seen between some particular circling miRNAs and glomerular filtration rate, a notable boundary of kidney sickness movement. Huge scope of forthcoming investigations zeroing in on diabetic patients going through renal disappointment will be important to recognize a particular miRNA profile in plasma or pee, foreseeing the presence of this difficulty. Pee addresses an optimal wellspring of miRNAs since it tends to be effectively gathered in a non-intrusive way and in huge sums [85].

Table 1. Types of diabetes complications.

SNo.	Attribute Name	Description
1.	CHF	Congestive Heart failure
2.	Foot Problem	Raised blood sugar can harm circulation, slows the healing of cuts and sores, and nerve damage can interfere with your ability to feel your feet.
3.	Stroke and Heart attack	Stroke and Heart attack
4.	Blindness	Blindness
5.	ESRF	End Stage Renal failure

Also, urinary exosomes start from different cell types traversing over the whole urinary tract and would be fit to screen for the movement of renal infections. In reality, urinary miRNA profiles were, as of late, answered to contrast across the phases of diabetic nephropathy, recommending that they might be utilized as apparatuses to follow the reformist change of the renal processes [86]. As far as anyone is concerned, there is currently no distributed report about the utilization of circling miRNAs to foresee diabetic retinopathy. Nonetheless, ongoing investigations have shown an inclusion of some particular miRNAs in improving this confusion. These discoveries might make way for future examinations to evaluate the expected utilization of miRNAs as indicators of this crippling condition.

4.1. Gestational diabetes.

On a basic level, flowing miRNAs could also be utilized to recognize ladies at greater risk of creating gestational diabetes. Currently, most screening conventions depend on a glucose challenge test performed around the 24-28th gestational weeks. Subsequently, intercessions like eating regimen, exercise, or drugs, are here and there and begin as late as the 32nd seven-day stretch of development. In a multistage review study, miRNAs were separated serum of ladies at 16-19 weeks of incubation, and three miRNAs (miR-29a, - 122, and - 132) were recognized to be liberated in ladies creating gestational diabetes before distinguishable changes in blood glucose levels [87]. Placental-explicit miRNAs can be identified in maternal serum, hence, making it conceivable that gestational diabetes might prompt changes in blood miRNAs that contrast from those of T1DM or T2DM.



Figure 1. Etiology of gestational diabetes mellitus.

5. Conclusions and Future Directions

The discoveries above affirm miRNAs' engaging quality as clever biomarkers for diabetes. For sure, changes in the levels of a subset of these little RNA atoms in body liquids vows to give new insights for early recognizable proof of people in danger to foster diabetes and their related difficulties, for following infection movement, or for surveying the adequacy of remedial intercessions [88]. Notwithstanding, as examined beneath, major logical and specialized advances should be made before these objectives can be accomplished. Circling miRNAs should substitute or supplement other routine estimations. Subsequently, their adequacy in anticipating the presence of diabetes or its intricacies should be methodically contrasted with effectively accessible biomarkers. Specifically, it will be fundamental to examine whether miRNAs are for sure ready to give prior or potentially more exact discovery of people in danger of fostering the infection or its drawn-out inconveniences. The circumstance will ideally advance later on. However, for most distributed investigations, there is, for the second, no conspicuous benefit of supplanting other customary biomarkers with estimations of circling miRNA levels [89]. The level of certain plasma miRNAs is extraordinarily impacted by the level of hemolysis and by cell defilement, delivering

them less reasonable as clinical biomarkers. Diabetes mellitus is a perplexing issue, including major metabolic adjustments and significant variations in the movement of a few organs. miRNAs are proposed as likely biomarkers for the expanding number of infection states. Accordingly, it will be fundamental to decide if the recognized miRNA changes are solely characteristic of a prediabetic or diabetic condition or then again in case they are noticed likewise in other physiological or obsessive circumstances., for example, in light of alterations in the wholesome state, irritation, autoimmunity, malignant growth, etc. As of now, the beginning of blood miRNAs is, to a great extent, obscure, and their levels don't straightforwardly reflect the change in pancreatic β-cells or insulin target tissues happening in diabetes [90,92]. miRNAs can be effectively or inactively delivered by an assortment of cells and can be conveyed by layer-bound vesicles, protein edifices, or lipoprotein particles. Nonetheless, adjustments in the degree of miRNAs beginning from explicit gatherings of cells that are not in direct contact with the blood or are not extremely plentiful are probably not going to affect the pool of plasmatic miRNAs essentially and will likely go undetected. Albeit requesting conventions permitting a particular appraisal of the miRNAs conveyed by exosomes, protein edifices, or lipoproteins will likely outfit more nitty-gritty data about the physiological or obsessive status of the organs of interest. Besides, it very well might be feasible to cleanse film-bound vesicles starting from a particular gathering of cells exploiting the presence of trademark proteins on the vesicle surface. In any case, the statement of this specific miRNA is changed in an assortment of tumor cells, and a few creators have proposed utilizing flowing levels of this noncoding RNA for the determination of various sorts of malignant growth. A few insulin-emitting cell lines discharge critical measures of exosomes, and there is starting proof demonstrating that this is the case for rat and human islet cells [91,93,94]. Conventions allowing the advancement of exosomes obtained from islet cells would presumably work on the recognition of explicit changes in insulin-emitting cells and give a superior assessment of the utilitarian β-cell mass.

Funding

This research received no external funding.

Acknowledgments

The team of authors thanks their respective workplaces for nurturing a scientific vision for compiling a review on "Biomarkers in Diabetes mellitus (DM) - with a special focus on miRNAs as future markers for diagnosis of DM". MJM and WS acknowledge SKIMS-Srinagar, (J&K) India, VG Acknowledge AIIMS Bhopal, India, AAS acknowledges National Institute of Biologicals, Noida (U.P.) India, GC acknowledges ICMR-CAR School of Biotechnology, SMVDU Katra (J&K) India.

Conflicts of Interest

The authors declare no conflict of interest regarding this paper submission.

References

1. Taskinen, M.-R.; Borén, J.J.A. New insights into the pathophysiology of dyslipidemia in type 2 diabetes. **2015**, *239*, 483-495, https://doi.org/10.1016/j.atherosclerosis.2015.01.039.
2. Bakker, K.; Schaper, N.; Board, I.W.G.o.t.D.F.E. The development of global consensus guidelines on the management and prevention of the diabetic foot 2011. *Diabetes/metabolism research and reviews* **2012**, *28*, 116-118, https://doi.org/10.1002/dmrr.2254
3. Goh, T.C.; Bajuri, M.Y.; Nadarajah, S.C.; Rashid, A.H.A.; Baharuddin, S.; Zamri, K.S. Clinical and bacteriological profile of diabetic foot infections in a tertiary care. *Journal of foot and ankle research* **2020**, *13*, 1-8, https://doi.org/10.1186/s13047-020-00406-y
4. Flora, G.D.; Nayak, M.K. A brief review of cardiovascular diseases, associated risk factors and current treatment regimes. *Current pharmaceutical design* **2019**, *25*, 4063-4084, https://doi.org/10.2174/1381612825666190925163827.
5. Eitner, A.; Culvenor, A.G.; Wirth, W.; Schaible, H.G.; Eckstein, F. Impact of diabetes mellitus on knee osteoarthritis pain and physical and mental status: data from the osteoarthritis initiative. *Arthritis care & research* **2021**, *73*, 540-548, https://doi.org/10.1002/acr.24173.
6. Azevedo, M.; Alla, S.J.I.j.o.d.i.d.c. Diabetes in sub-saharan Africa: kenya, mali, mozambique. *Nigeria, South Africa and zambia*. **2008**, *28*, 101, https://doi.org/10.4103/0973-3930.45268.
7. Gao, H.X.; Regier, E.E.; Close, K.L.J.J.o.d. International Diabetes Federation World Diabetes Congress 2015. *Journal of Diabets* **2016**, *8*, 300-302, https://doi.org/10.1111/1753-0407.12377. ,
8. Bajaj, S. RSSDI clinical practice recommendations for the management of type 2 diabetes mellitus 2017. *International journal of diabetes in developing countries* **2018**, *38*, 1-115, https://doi.org/10.1007/s13410-018-0604-7.
9. Ibrahim, A.M. The epidemiology of the diabetes epidemic: a growing public health concern. *South African Journal of Diabetes* **2017**, *10*, 7-11, https://doi.org/10520/EJC-9233d4460.
10. Anjana, R.M.; Deepa, M.; Pradeepa, R.; Mahanta, J.; Narain, K.; Das, H.K.; Adhikari, P.; Rao, P.V.; Saboo, B.; Kumar, A.J.T.l.D.; et al. Prevalence of diabetes and prediabetes in 15 states of India: *results from the ICMR–INDIAB population-based cross-sectional study.* **2017**, *5*, 585-596, https://doi.org/10.1016/S2213-8587(17)30174-2.
11. Vijayakumar, G.; Manghat, S.; Vijayakumar, R.; Simon, L.; Scaria, L.M.; Vijayakumar, A.; Sreehari, G.K.; Kutty, V.R.; Rachana, A.; Jaleel, A. Incidence of type 2 diabetes mellitus and prediabetes in Kerala, India: results from a 10-year prospective cohort. *BMC public health* **2019**, *19*, 1-10, https://doi.org/10.1186/s12889-019-6445-6.
12. Han, J.C.; Weiss, R. Obesity, Metabolic Syndrome and Disorders of Energy Balance. In *Sperling Pediatric Endocrinology*; Elsevier: **2021**; pp. 939-1003, https://doi.org/10.1016/B978-0-323-62520-3.00024-5.
13. Muchtar, E.; Blauwet, L.A.; Gertz, M.A.J.C.r. Restrictive cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy. Circulation Research **2017**, *121*, 819-837, https://doi.org/10.1161/CIRCRESAHA.117.310982.
14. WHO. Diabeties. *http://www.who.int/news-room/fact-sheets/detail/diabetes.* **2020**.
15. Katsarou, A.; Gudbjornsdottir, S.; Rawshani, A.; Dabelea, D.; Bonifacio, E.; Anderson, B.J.; Jacobsen, L.M.; Schatz, D.A.; Lernmark, A.J.N.r.D.p. Type 1 *diabetes mellitus. Nature reviews* **2017**, *3*, 1-17, https://doi.org/10.1038/nrdp.2017.16 .
16. Craig, M.E.; Kim, K.W.; Isaacs, S.R.; Penno, M.A.; Hamilton-Williams, E.E.; Couper, J.J.; Rawlinson, W.D.J.D. Early-life factors contributing to type 1 diabetes. *Springer link* **2019**, *62*, 1823-1834, https://doi.org/10.1007/s00125-019-4942-x.
17. Gupta, A.; Behl, T.; Sachdeva, M.J.O.M. Key milestones in the diabetes research: A comprehensive update. *Obesity Medicine* **2020**, *17*, 100183, https://doi.org/10.1016/j.obmed.2020.100183.
18. Gupta, A.; Behl, T.; Panichayupakaranan, P.J.O.M. A review of phytochemistry and pharmacology profile of *Juglans regia*. Obesity Medicine **2019**, *16*, 100142, https://doi.org/10.1016/j.obmed.2019.100142.
19. Ajjan, R.A.; Schroeder, V.J.M.i. Role of complement in diabetes. *Molecular Imunology* **2019**, *114*, 270-277, https://doi.org/10.1016/j.molimm.2019.07.031.
20. Association, A.D. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes—2020. *Diabetes care* **2020**, *43*, S14-S31, https://doi.org/10.2337/dc20-S002.

21. Batista, T.M.; Jayavelu, A.K.; Albrechtsen, N.J.W.; Iovino, S.; Lebastchi, J.; Pan, H.; Dreyfuss, J.M.; Krook, A.; Zierath, J.R.; Mann, M. A cell-autonomous signature of dysregulated protein phosphorylation underlies muscle insulin resistance in type 2 diabetes. *Cell metabolism* **2020**, *32*, 844-859. e845, https://doi.org/10.1016/j.cmet.2020.08.007.
22. Hussain, T.; Tan, B.; Murtaza, G.; Liu, G.; Rahu, N.; Kalhoro, M.S.; Kalhoro, D.H.; Adebowale, T.O.; Mazhar, M.U.; ur Rehman, Z. Flavonoids and type 2 diabetes: Evidence of efficacy in clinical and animal studies and delivery strategies to enhance their therapeutic efficacy. *Pharmacological research* **2020**, *152*, 104629, https://doi.org/10.1016/j.phrs.2020.104629.
23. Ludvigsson, J. Therapies to preserve β-cell function in type 1 diabetes. Ludvigsson, J. Therapies to preserve β-cell function in type 1 diabetes. *Drugs* **2016**, *76*, 169-185, https://doi.org/10.1007/s40265-015-0511-x.
24. Dounousi, E.; Duni, A.; Leivaditis, K.; Vaios, V.; Eleftheriadis, T.; Liakopoulos, V. Improvements in the management of diabetic nephropathy. *The review of diabetic studies: RDS* **2015**, *12*, 119, https://doi.org/10.1900/RDS.2015.12.119.
25. Jain, K.K.; Jain, K.K. The handbook of biomarkers; *Springer:* **2010**, https://doi.org/10.1007/978-1-4939-7431-3.
26. DiMeglio, L.A.; Evans-Molina, C.; Oram, R.A. Type 1 diabetes. *The Lancet* **2018**, *391*, 2449-2462, https://doi.org/10.1016/S0140-6736(18)31320-5.
27. Maestú, F.; Cuesta, P.; Hasan, O.; Fernandéz, A.; Funke, M.; Schulz, P.E.J.F.i.h.n. The importance of the validation of M/EEG with current biomarkers in Alzheimer's disease. **2019**, *13*, 17, https://doi.org/10.3389/fnhum.2019.00017.
28. Yi, L.; Swensen, A.C.; Qian, W.-J. Serum biomarkers for diagnosis and prediction of type 1 diabetes. *Translational Research* **2018**, *201*, 13-25, https://doi.org/10.1016/j.trsl.2018.07.009.
29. Kahn, S.E.; Chen, Y.-C.; Esser, N.; Taylor, A.J.; van Raalte, D.H.; Zraika, S.; Verchere, C.B. The β Cell in Diabetes: Integrating Biomarkers with Functional Measures. *Endocrine Reviews* **2021,** https://doi.org/10.1210/endrev/bnab021.
30. Warshauer, J.T.; Bluestone, J.A.; Anderson, M.S.J.C.m. New frontiers in the treatment of type 1 diabetes. *Cell Metabolism* **2020**, *31*, 46-61, https://doi.org/10.1016/j.cmet.2019.11.017.
31. Vallianou, N.G.; Stratigou, T.; Geladari, E.; Tessier, C.M.; Mantzoros, C.S.; Dalamaga, M. Diabetes type 1: Can it be treated as an autoimmune disorder? Reviews in Endocrine and Metabolic Disorders. *Springer* **2021**, 1-18, https://doi.org/10.1007/s11154-021-09642-4
32. Domingueti, C.P.; Fóscolo, R.B.; Reis, J.S.; Campos, F.M.F.; Dusse, L.M.S.; Carvalho, M.d.G.; Braga Gomes, K.; Fernandes, A.P.J.J.o.d.r. Association of haemostatic and inflammatory biomarkers with nephropathy in type 1 diabetes mellitus. Journal of Diabets Research **2016**, https://doi.org/10.1155/2016/2315260.
33. Laakso, M.J.M.m. Biomarkers for type 2 diabetes. *Molecular Metabolism* **2019**, *27*, S139-S146, https://doi.org/10.1016/j.molmet.2019.06.016.
34. Bellou, V.; Belbasis, L.; Tzoulaki, I.; Evangelou, E.J.P.o. Risk factors for type 2 diabetes mellitus: an exposure-wide umbrella review of meta-analyses. *Plos One* **2018**, *13*, e0194127, https://doi.org/10.1371/journal.pone.0194127.
35. Wen, J.; Yuan, H. Independent association between the visceral adiposity index and microalbuminuria in patients with newly diagnosed type 2 diabetes. *Diabetes/metabolism research and reviews* . **2020**, *36*, e3198, https://doi.org/10.1002/dmrr.3198.
36. Laakso, M.; Kuusisto, J.; Stančáková, A.; Kuulasmaa, T.; Pajukanta, P.; Lusis, A.J.; Collins, F.S.; Mohlke, K.L.; Boehnke, M.J.J.o.l.r. The Metabolic Syndrome in Men study: a resource for studies of metabolic and cardiovascular diseases. Journal of Lipid Research **2017**, *58*, 481-493, https://doi.org//10.1194/jlr.O072629.
37. Laakso, M. Biomarkers for type 2 diabetes. *Molecular metabolism* **2019**, *27*, S139-S146, https://doi.org/10.1016/j.molmet.2019.06.016.
38. Porcu, E.; Gilardi, F.; Darrous, L.; Yengo, L.; Bararpour, N.; Gasser, M.; Marques-Vidal, P.; Froguel, P.; Waeber, G.; Thomas, A.; et al. Triangulating evidence from longitudinal and Mendelian randomization studies of metabolomic biomarkers for type 2 diabetes. *Scientific Reports* **2021**, *11*, 6197, https://doi.org/10.1038/s41598-021-85684-7.
39. Eddy, S.R. Non–coding RNA genes and the modern RNA world. *Nature Reviews Genetics* **2001**, *2*, 919-929, https://doi.org/10.1038/35103511.

40. Chan, J.J.; Tay, Y.J.I.j.o.m.s. Noncoding RNA: RNA regulatory networks in cancer. *Int. J. Mol. Sci* **2018**, *19*, 1310, https://doi.org/10.3390/ijms19051310.
41. Felekkis, K.; Touvana, E.; Stefanou, C.; Deltas, C. microRNAs: a newly described class of encoded molecules that play a role in health and disease. *Hippokratia* **2010**, *14*, 236, https://pubmed.ncbi.nlm.nih.gov/21311629/.
42. Bartel, D.P.J.c. MicroRNAs: target recognition and regulatory functions. *Cell* **2009**, *136*, 215-233, https://doi.org/10.1016/j.cell.2009.01.002.
43. Fabian, M.R.; Sonenberg, N.; Filipowicz, W.J.A.r.o.b. Regulation of mRNA translation and stability by microRNAs. *Annual Review of Biochemistry* **2010**, 79, 351-379, https://doi.org/10.1146/annurev-biochem-060308-103103.
44. Griffiths-Jones, S.; Saini, H.K.; Van Dongen, S.; Enright, A.J.J.N.a.r. miRBase: tools for microRNA genomics. *Nucleic Acids Research* **2007**, *36*, D154-D158, https://doi.org/10.1093/nar/gkm952.
45. Hashimoto, N.; Tanaka, T.J.J.o.h.g. Role of miRNAs in the pathogenesis and susceptibility of diabetes mellitus. *Journal of Human Genetics* **2017**, *62*, 141-150, https://doi.org/10.1038/jhg.2016.150.
46. de Jesus, D.S.; Mak, T.C.; Wang, Y.-F.; von Ohlen, Y.; Bai, Y.; Kane, E.; Chabosseau, P.; Chahrour, C.M.; Distaso, W.; Salem, V. Dysregulation of the Pdx1/Ovol2/Zeb2 axis in dedifferentiated β-cells triggers the induction of genes associated with epithelial–mesenchymal transition in diabetes. *Molecular Metabolism* **2021**, *53*, 101248, https://doi.org//10.1016/j.molmet.2021.101248.
47. Ji, C.; Guo, X. The clinical potential of circulating microRNAs in obesity. *Nature Reviews Endocrinology* **2019**, *15*, 731-743, https://doi.org/10.1038/s41574-019-0260-0.
48. Regazzi, R. MicroRNAs as therapeutic targets for the treatment of diabetes mellitus and its complications. *Expert opinion on therapeutic targets* **2018**, *22*, 153-160, https://doi.org/10.1080/14728222.2018.1420168.
49. Geisler, S.; Coller, J. RNA in unexpected places: long noncoding RNA functions in diverse cellular contexts. *Nature reviews Molecular cell biology* **2013**, *14*, 699-712, https://doi.org//10.1038/nrm3679.
50. Castell-Auvi, A.; Cedo, L.; Movassat, J.; Portha, B.; Sanchez-Cabo, F.; Pallares, V.; Blay, M.; Pinent, M.; Ardevol, A. Procyanidins modulate microRNA expression in pancreatic islets. *Journal of agricultural and food chemistry* **2013**, *61*, 355-363, https://doi.org/10.1021/jf303972f.
51. Snowhite, I.V.; Allende, G.; Sosenko, J.; Pastori, R.L.; Cayetano, S.M.; Pugliese, A. Association of serum microRNAs with islet autoimmunity, disease progression and metabolic impairment in relatives at risk of type 1 diabetes. *Diabetologia* **2017**, *60*, 1409-1422, https://doi.org/10.1007/s00125-017-4294-3.
52. Shantikumar, S.; Caporali, A.; Emanueli, C. Role of microRNAs in diabetes and its cardiovascular complications. *Cardiovascular research* **2012**, *93*, 583-593, https://doi.org/10.1093/cvr/cvr300.
53. Williams, M.D.; Mitchell, G.M.J.E.d.r. MicroRNAs in insulin resistance and obesity. Journal of Diabets Research **2012**, *2012*, https://doi.org/10.1155/2012/484696.
54. Hashimoto, N.; Tanaka, T. Role of miRNAs in the pathogenesis and susceptibility of diabetes mellitus. *Journal of human genetics* **2017**, *62*, 141-150, https://doi.org/10.1038/jhg.2016.150.
55. Sekar, D.; Venugopal, B.; Sekar, P.; Ramalingam, K. Role of microRNA 21 in diabetes and associated/related diseases. *Gene* **2016**, *582*, 14-18, https://doi.org/10.1016/j.gene.2016.01.039.
56. Kaur, P.; Kotru, S.; Singh, S.; Behera, B.S.; Munshi, A.J.J.o.P.; Biochemistry. Role of miRNAs in the pathogenesis of T2DM, insulin secretion, insulin resistance, and β cell dysfunction: the story so far. *Springer* **2020**, 1-18, https://doi.org/10.1007/s13105-020-00760-2.
57. Shirakawa, J.; De Jesus, D.; Kulkarni, R. Exploring inter-organ crosstalk to uncover mechanisms that regulate β-cell function and mass. *European journal of clinical nutrition* **2017**, *71*, 896-903, https://doi.org/10.1038/ejcn.2017.13.
58. Guay, C.; Regazzi, R. Circulating microRNAs as novel biomarkers for diabetes mellitus. *Nature Reviews Endocrinology* **2013**, *9*, 513-521, https://doi.org/10.1038/nrendo.2013.86.
59. Guay, C.; Regazzi, R.J.N.R.E. Circulating microRNAs as novel biomarkers for diabetes mellitus. *Nature Review Endocrinolgy* **2013**, *9*, 513, https://doi.org/10.1038/nrendo.2013.86.
60. Zampetaki, A.; Kiechl, S.; Drozdov, I.; Willeit, P.; Mayr, U.; Prokopi, M.; Mayr, A.; Weger, S.; Oberhollenzer, F.; Bonora, E.J.C.r. Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes. *Circulation Research* **2010**, *107*, 810-817, https://doi.org/10.1161/CIRCRESAHA.110.226357

61. Ortega, F.J.; Mercader, J.M.; Moreno-Navarrete, J.M.; Rovira, O.; Guerra, E.; Esteve, E.; Xifra, G.; Martínez, C.; Ricart, W.; Rieusset, J.J.D.c. Profiling of circulating microRNAs reveals common microRNAs linked to type 2 diabetes that change with insulin sensitization. *Diabets Care* **2014**, *37*, 1375-1383, https://doi.org/10.2337/dc13-1847.
62. Raffort, J.; Hinault, C.; Dumortier, O.; Van Obberghen, E.J.D. Circulating microRNAs and diabetes: potential applications in medical practice. *Springer* **2015**, *58*, 1978-1992, https://doi.org/10.1007/s00125-015-3680-y.
63. Cortez, M.A.; Bueso-Ramos, C.; Ferdin, J.; Lopez-Berestein, G.; Sood, A.K.; Calin, G.A. MicroRNAs in body fluids—the mix of hormones and biomarkers. *Nature reviews Clinical oncology* **2011**, *8*, 467-477, https://doi.org/10.1038/nrclinonc.2011.76.
64. De Jesus, D.F.; Kulkarni, R.N. "Omics" and "epi-omics" underlying the β-cell adaptation to insulin resistance. *Molecular metabolism* **2019**, *27*, S42-S48, https://doi.org/10.1016/j.molmet.2019.06.003.
65. Hulsmans, M.; Holvoet, P. MicroRNA-containing microvesicles regulating inflammation in association with atherosclerotic disease. *Cardiovascular research* **2013**, *100*, 7-18, https://doi.org/10.1093/cvr/cvt161.
66. Tonge, D.; Gant, T.J.B.m.b. What is normal? Next generation sequencing-driven analysis of the human circulating miRNAOme. *BMC Biology Molecular* **2016**, *17*, 1-12, https://doi.org/10.1186/s12867-016-0057-9.
67. Latreille, M.; Herrmanns, K.; Renwick, N.; Tuschl, T.; Malecki, M.T.; McCarthy, M.I.; Owen, K.R.; Rülicke, T.; Stoffel, M.J.J.o.m.m. miR-375 gene dosage in pancreatic β-cells: implications for regulation of β-cell mass and biomarker development. *Springer* **2015**, *93*, 1159-1169, https://doi.org/10.1007/s00109-015-1296-9.
68. Hackl, M.; Heilmeier, U.; Weilner, S.; Grillari, J. Circulating microRNAs as novel biomarkers for bone diseases–Complex signatures for multifactorial diseases? *Molecular and cellular endocrinology* **2016**, *432*, 83-95, https://doi.org/10.1016/j.mce.2015.10.015.
69. Gonzalez-Sánchez, L.E.; Ortega-Camarillo, C.; Contreras-Ramos, A.; Barajas-Nava, L.A.J.J.o.D. miRNAs as biomarkers for diagnosis of type 2 diabetes: A systematic review. *Journal of Diabetes* **2021**, https://doi.org//10.1111/1753-0407.13166.
70. Willmer, T.; Johnson, R.; Louw, J.; Pheiffer, C. Blood-based DNA methylation biomarkers for type 2 diabetes: potential for clinical applications. *Frontiers in endocrinology* **2018**, *9*, 744, https://doi.org/10.3389/fendo.2018.00744.
71. Karolina, D.S.; Armugam, A.; Tavintharan, S.; Wong, M.T.; Lim, S.C.; Sum, C.F.; Jeyaseelan, K.J.P.o. MicroRNA 144 impairs insulin signaling by inhibiting the expression of insulin receptor substrate 1 in type 2 diabetes mellitus. *Plos One* **2011**, *6*, e22839, https://doi.org/10.1371/journal.pone.0022839.
72. Seyhan, A.A.; Lopez, Y.O.N.; Xie, H.; Yi, F.; Mathews, C.; Pasarica, M.; Pratley, R.E.J.S.r. Pancreas-enriched miRNAs are altered in the circulation of subjects with diabetes: a pilot cross-sectional study. *Scientific Reports* **2016**, *6*, 1-15, https://doi.org/10.1038/srep31479.
73. Garcia-Contreras, M.; Shah, S.H.; Tamayo, A.; Robbins, P.D.; Golberg, R.B.; Mendez, A.J.; Ricordi, C. Plasma-derived exosome characterization reveals a distinct microRNA signature in long duration Type 1 diabetes. *Scientific reports* **2017**, *7*, 1-10, https://doi.org/10.1038/s41598-017-05787-y.
74. Alexandru, N.; Procopciuc, A.; Vîlcu, A.; Comarița, I.K.; Bădilă, E.; Georgescu, A. Extracellular vesicles—incorporated microRNA signature as biomarker and diagnosis of prediabetes state and its complications. *Reviews in Endocrine and Metabolic Disorders* **2021**, 1-24, https://doi.org/10.1007/s11154-021-09664-y.
75. Salas-Pérez, F.; Cuevas-Sierra, A.; Cuervo, M.; Goni, L.; Milagro, F.I.; Martínez, J.A.; Riezu-Boj, J.I. Differentially methylated regions (DMRs) in PON3 gene between responders and non-responders to a weight loss dietary intervention: a new tool for precision management of obesity. *Epigenetics* **2021**, 1-12, https://doi.org/10.1080/15592294.2021.1873629.
76. Grieco, G.E.; Brusco, N.; Licata, G.; Nigi, L.; Formichi, C.; Dotta, F.; Sebastiani, G. Targeting microRNAs as a therapeutic strategy to reduce oxidative stress in diabetes. *International journal of molecular sciences* **2019**, *20*, 6358, https://doi.org/10.3390/ijms20246358.
77. Prabu, P.; Rome, S.; Sathishkumar, C.; Aravind, S.; Mahalingam, B.; Shanthirani, C.S.; Gastebois, C.; Villard, A.; Mohan, V.; Balasubramanyam, M.J.P.o. Circulating miRNAs of 'Asian Indian phenotype'identified in subjects with impaired glucose tolerance and patients with type 2 diabetes. *Plos One* **2015**, *10*, e0128372, https://doi.org/10.1371/journal.pone.0128372.

78. Van Duinkerken, E.; Ryan, C.M. Diabetes mellitus in the young and the old: Effects on cognitive functioning across the life span. *Neurobiology of disease* **2020**, *134*, 104608, https://doi.org/10.1016/j.nbd.2019.104608.
79. Shahi, A.; Prasad, V.; Imam, S.S.; Muheem, A.; Jahangir, M.A. Pathophysiological Ramifications of Diabetic Condition: A Review. *Asian Journal of Biomedical and Pharmaceutical Sciences* **2018**, *8*, 28-38, https://doi.org/10.4066/2249-622X.65.18-845.
80. Manay, P.; Turgeon, N.; Axelrod, D.A. Role of Whole Organ Pancreas Transplantation in the Day of Bioartificial and Artificial Pancreas. *Current Transplantation Reports* **2020**, 1-7, https://link.springer.com/article/10.1007/s40472-020-00300-3.
81. Selby, N.M.; Taal, M.W. An updated overview of diabetic nephropathy: Diagnosis, prognosis, treatment goals and latest guidelines. Diabetes. *Obesity and Metabolism* **2020**, *22*, 3-15.Chukwuma Sr, C. Comorbid presentations and coronary heart disease risks with type 1 diabetes mellitus. *Austin Medical Sciences* **2019**, *4*, https://doi.org/10.1111/dom.14007.
82. Benameur, T.; Osman, A.; Parray, A.; Ait Hssain, A.; Munusamy, S.; Agouni, A. Molecular mechanisms underpinning microparticle-mediated cellular injury in cardiovascular complications associated with diabetes. *Oxidative medicine and cellular longevity* **2019**, *2019*, https://doi.org/10.1155/2019/6475187.
83. Manay, P.; Turgeon, N.; Axelrod, D.A. Role of Whole Organ Pancreas Transplantation in the Day of Bioartificial and Artificial Pancreas. *Current Transplantation Reports* **2020**, 1-7, https://doi.org/10.1007/s40472-020-00300-3.
84. Selby, N.M.; Taal, M.W. An updated overview of diabetic nephropathy: Diagnosis, prognosis, treatment goals and latest guidelines. *Diabetes, Obesity and Metabolism* **2020**, *22*, 3-15, https://doi.org/10.1111/dom.14007.
85. Chukwuma Sr, C. Comorbid presentations and coronary heart disease risks with type 1 diabetes mellitus. *Austin Medical Sciences* **2019**, *4*, https://austinpublishinggroup.com/medical-sciences/fulltext/ams-v4-id1037.php.
86. Benameur, T.; Osman, A.; Parray, A.; Ait Hssain, A.; Munusamy, S.; Agouni, A. Molecular mechanisms underpinning microparticle-mediated cellular injury in cardiovascular complications associated with diabetes. *Oxidative medicine and cellular longevity* **2019**, https://doi.org/10.1155/2019/6475187.
87. Li, N.; Zhou, H.; Tang, Q. Red blood cell distribution width: a novel predictive indicator for cardiovascular and cerebrovascular diseases. *Disease Markers* **2017**, https://doi.org/10.1155/2017/7089493
88. Saenz-Pipaon, G.; Echeverria, S.; Orbe, J.; Roncal, C. Urinary Extracellular Vesicles for Diabetic Kidney Disease Diagnosis. *Journal of Clinical Medicine* **2021**, *10*, 2046, https://doi.org/10.3390/jcm10102046.
89. Kim, S.H.; MacIntyre, D.A.; Binkhamis, R.; Cook, J.; Sykes, L.; Bennett, P.R.; Terzidou, V. Maternal plasma miRNAs as potential biomarkers for detecting risk of small-for-gestational-age births. *EBioMedicine* **2020**, *62*, 103145, https://doi.org/10.1016/j.ebiom.2020.103145.
90. Gonder-Frederick, L.A.; Cox, D.J.; Ritterband, L.M. Diabetes and behavioral medicine: the second decade. *Journal of consulting and clinical psychology* **2002**, *70*, 611, https://doi.org/10.1037/0022-006X.70.3.611.
91. Spinks, J.J.; Mann, N.P. Improving the long-term outlook for children with diabetes mellitus. *Paediatrics and Child Health* **2013**, *23*, 168-173, https://doi.org/10.1016/j.paed.2012.12.008
92. Pavkov, M.E.; Bennett, P.H.; Knowler, W.C.; Krakoff, J.; Sievers, M.L.; Nelson, R.G. Effect of youth- onset type 2 diabetes mellitus on incidence of end-stage renal disease and mortality in young and middle-aged Pima Indians. *Jama* **2006**, *296*, 421-426, https://doi.org/10.1001/jama.296.4.421
93. Schnell, O.; Valensi, P.; Standl, E.; Ceriello, A. Comparison of mechanisms and transferability of outcomes of SGLT2 inhibition between type 1 and type 2 diabetes. *Endocrinology, Diabetes & Metabolism* **2020**, *3*, e00129, https://doi.org/10.1002/edm2.129.